Latest stories on DRTS
DRTS highlights FDA clearance to expand REGAIN glioblastoma trial from 10 to 20 patients ahead of SNO 2026 data presentation
October 19, 2026
MarketChameleon58 · neutralproduct/pr
Alpha Tau to Participate in October Investor Conferences
Business Insider56 · neutralgeneral
Alpha Tau to Participate in October Investor Conferences
GlobeNewswire55 · neutralgeneral
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough
Seeking Alpha73 · bullishproduct/pr
Nadav Kidron’s Appointment to Nano Dimension’s Board Signals Strategic Shift for Alpha Tau Medical’s Governance
August 17, 2026
MarketChameleon56 · neutralgeneral
Alpha Tau Medical GAAP EPS of -$0.25
Seeking Alpha28 · bearishearnings
Alpha Tau plans dual listing on Nasdaq and TASE to expand access for Israeli investors
Seeking Alpha63 · neutralgeneral
Alpha Tau Posts Strong Alpha DaRT–Keytruda Data in Head and Neck Cancer Study
TipRanks73 · bullishproduct/pr
Alpha Tau Treats First Recurrent Glioblastoma Patient Outside U.S. With Alpha DaRT in Israel
TipRanks63 · neutralproduct/pr
Alpha Tau Medical: A Lot Of Shots On Goal
Seeking Alpha58 · neutralproduct/pr
Alpha Tau Posts Strong Pancreatic Cancer Survival Data for Alpha DaRT at 2026 ASCO
TipRanks73 · bullishproduct/pr
Alpha Tau Medical GAAP EPS of -$0.26
Seeking Alpha28 · bearishearnings